These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26380231)

  • 1. DESIGNING DRUG TRIALS FOR SARCOPENIA IN OLDER ADULTS WITH HIP FRACTURE - A TASK FORCE FROM THE INTERNATIONAL CONFERENCE ONFRAILTY AND SARCOPENIA RESEARCH (ICFSR).
    Vellas B; Fielding R; Miller R; Rolland Y; Bhasin S; Magaziner J; Bischoff-Ferrari H
    J Frailty Aging; 2014; 3(4):199-204. PubMed ID: 26380231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing consensus criteria for sarcopenia: an update.
    McLean RR; Kiel DP
    J Bone Miner Res; 2015 Apr; 30(4):588-92. PubMed ID: 25735999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE.
    Cesari M; Fielding R; Bénichou O; Bernabei R; Bhasin S; Guralnik JM; Jette A; Landi F; Pahor M; Rodriguez-Manas L; Rolland Y; Roubenoff R; Sinclair AJ; Studenski S; Travison T; Vellas B
    J Frailty Aging; 2015; 4(3):114-120. PubMed ID: 26366378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty.
    Rodriguez-Mañas L; Araujo de Carvalho I; Bhasin S; Bischoff-Ferrari HA; Cesari M; Evans W; Hare JM; Pahor M; Parini A; Rolland Y; Fielding RA; Walston J; Vellas B
    J Frailty Aging; 2020; 9(1):4-8. PubMed ID: 32150207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force.
    Vellas B; Fielding R; Bhasin S; Cerreta F; Goodpaster B; Guralnik JM; Kritchevsky S; Legrand V; Forkin C; Magaziner J; Morley JE; Rodriguez-Manas L; Roubenoff R; Studenski S; Villareal DT; Cesari M;
    J Frailty Aging; 2016; 5(4):194-200. PubMed ID: 27883164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force.
    Vellas B; Fielding RA; Bens C; Bernabei R; Cawthon PM; Cederholm T; Cruz-Jentoft AJ; Del Signore S; Donahue S; Morley J; Pahor M; Reginster JY; Rodriguez Mañas L; Rolland Y; Roubenoff R; Sinclair A; Cesari M
    J Frailty Aging; 2018; 7(1):2-9. PubMed ID: 29412436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically Meaningful Change for Physical Performance: Perspectives of the ICFSR Task Force.
    Guralnik J; Bandeen-Roche K; Bhasin SAR; Eremenco S; Landi F; Muscedere J; Perera S; Reginster JY; Woodhouse L; Vellas B
    J Frailty Aging; 2020; 9(1):9-13. PubMed ID: 32150208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutritional Intervention in Sarcopenia: Report from the International Conference on Frailty and Sarcopenia Research Task Force.
    Landi F; Sieber C; Fielding RA; Rolland Y; Guralnik J
    J Frailty Aging; 2018; 7(4):247-252. PubMed ID: 30298173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.
    Cesari M; Fielding RA; Pahor M; Goodpaster B; Hellerstein M; van Kan GA; Anker SD; Rutkove S; Vrijbloed JW; Isaac M; Rolland Y; M'rini C; Aubertin-Leheudre M; Cedarbaum JM; Zamboni M; Sieber CC; Laurent D; Evans WJ; Roubenoff R; Morley JE; Vellas B;
    J Cachexia Sarcopenia Muscle; 2012 Sep; 3(3):181-90. PubMed ID: 22865205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing Drug Trials for Frailty: ICFSR Task Force 2018.
    Pahor M; Kritchevsky SB; Waters DL; Villareal DT; Morley J; Hare JM; Vellas B
    J Frailty Aging; 2018; 7(3):150-154. PubMed ID: 30095144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study.
    Lee WJ; Liu LK; Peng LN; Lin MH; Chen LK;
    J Am Med Dir Assoc; 2013 Jul; 14(7):528.e1-7. PubMed ID: 23664768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public Health Need, Molecular Targets, and Opportunities for the Accelerated Development of Function-Promoting Therapies: Proceedings of a National Institute on Aging Workshop.
    Correa-de-Araujo R; Bhasin S
    J Gerontol A Biol Sci Med Sci; 2022 Nov; 77(11):2227-2237. PubMed ID: 36399442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of C-terminal agrin fragment (CAF) are associated with sarcopenia in older hip fractured patients.
    Marzetti E; Calvani R; Lorenzi M; Marini F; D'Angelo E; Martone AM; Celi M; Tosato M; Bernabei R; Landi F
    Exp Gerontol; 2014 Dec; 60():79-82. PubMed ID: 25304331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing falls and resulting hip fractures among older women.
    Stevens JA; Olson S
    MMWR Recomm Rep; 2000 Mar; 49(RR-2):3-12. PubMed ID: 15580729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resilience: Biological Basis and Clinical Significance - A Perspective Report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force.
    Cesari M; Azzolino D; LeBrasseur NK; Whitson H; Rooks D; Sourdet S; Angioni D; Fielding RA; Vellas B; Rolland Y
    J Frailty Aging; 2022; 11(4):342-347. PubMed ID: 36346720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of sarcopenia and reduced leg muscle mass in Japanese patients immediately after a hip fracture.
    Hida T; Ishiguro N; Shimokata H; Sakai Y; Matsui Y; Takemura M; Terabe Y; Harada A
    Geriatr Gerontol Int; 2013 Apr; 13(2):413-20. PubMed ID: 22816427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations.
    Vellas B; Pahor M; Manini T; Rooks D; Guralnik JM; Morley J; Studenski S; Evans W; Asbrand C; Fariello R; Pereira S; Rolland Y; Abellan van Kan G; Cesari M; Chumlea WC; Fielding R
    J Nutr Health Aging; 2013 Jul; 17(7):612-8. PubMed ID: 23933872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations in the development of drugs to treat sarcopenia.
    Brass EP; Sietsema KE
    J Am Geriatr Soc; 2011 Mar; 59(3):530-5. PubMed ID: 21361879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the Development of Drugs for Sarcopenia and Frailty - Report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force.
    Cesari M; Bernabei R; Vellas B; Fielding RA; Rooks D; Azzolino D; Mariani J; Oliva AA; Bhasin S; Rolland Y
    J Frailty Aging; 2022; 11(2):135-142. PubMed ID: 35441189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.